Evidence map›Paper›PMID 40036302›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2025

Differential hepatic activation of mouse and human peroxisome proliferator-activated receptor-α by perfluorohexane sulfonate.

Yahya Khan, Annalee M Schmidt, Kyle J Oldro, Xiaoyang Zhu, Angelina R Kramer, Sarah R Hamilton, Katherine O Bleil, Ryan M Krisko, Jeremiah D Zitzow, Yuan Tian and 6 more

Abstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Synergistic toxicity in alcohol-associated liver disease and PFAS exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yahya KhanDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.
Annalee M SchmidtDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.
Kyle J OldroDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.
Xiaoyang ZhuDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.
Angelina R KramerDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.
Sarah R HamiltonDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.
Katherine O BleilDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.
Ryan M Krisko3M Company, St Paul, MN 55144, United States.
Jeremiah D Zitzow3M Company, St Paul, MN 55144, United States.
Yuan TianDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.ORCID 0000-0001-6174-3359
Shu-Ching Chang3M Company, St Paul, MN 55144, United States.
Vonn WalterDepartment of Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States.ORCID 0000-0001-6114-6714
Samuel M CohenDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE 68182, United States.ORCID 0000-0002-5047-0962
Frank J GonzalezCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
Andrew D PattersonDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.ORCID 0000-0003-2073-0070
Jeffrey M PetersDepartment of Veterinary and Biomedical Science, The Pennsylvania State University, University Park, PA 16802, United States.

Funding

3M CompanyNational Institute of Food and Agriculture and Hatch AppropriationsUSDA
6 · The paper itself

Abstract

Exposure of perfluorohexane sulfonate (PFHxS) is associated with hepatomegaly and accumulation of lipids that may be mediated by nuclear receptors like peroxisome proliferator-activated receptor-α (PPARα), constitutive androstane receptor (CAR), or pregnane X receptor (PXR). This study tested the hypotheses that: (i) PFHxS causes changes in liver by activating PPARα, CAR, or PXR, and (ii) there is a species difference in PPARα activity by PFHxS. Wild-type, Ppara-null, and PPARA-humanized mice were fed either a control diet, or one containing 2.2 mg PFHxS/kg diet or 25.8 mg PFHxS/kg diet for either 7 or 28 days, and target gene expression was examined. Relative liver weights were similar after 7 days with either 2.2 or 25.8 mg PFHxS/kg dietary exposure compared with controls. Relative liver weights were higher after treatment for 28 days in all 3 genotypes fed 25.8 mg PFHxS/kg diet compared with controls. The concentration of PFHxS was dose-dependently increased in serum and liver compared with controls. PFHxS exposure of 2.2 and 25.8 mg PFHxS/kg diet caused an increase in expression of PPARα target genes in wild-type mice and this effect was not observed in similarly treated Ppara-null mice or PPARA-humanized mice. Administration of PFHxS caused increased expression of the CAR target gene Cyp2b10 in all 3 genotypes at both timepoints, and the PXR target gene Cyp3a11 in all 3 genotypes after 28 days. Exposure to PFHxS can increase liver weight due in part to the activation of mouse, but not human, PPARα. Activation of CAR and PXR by PFHxS also likely contributes to the observed hepatomegaly in all 3 genotypes.

Indexed as

FluorocarbonsLiverPPAR alphaSulfonic AcidsAnimalsConstitutive Androstane ReceptorHumansMaleMiceMice, Inbred C57BLMice, KnockoutOrgan SizePregnane X ReceptorReceptors, Cytoplasmic and NuclearReceptors, SteroidSpecies SpecificityConstitutive Androstane ReceptorFluorocarbonsperfluorohexanesulfonic acidPPAR alphaPPARA protein, humanPpara protein, mousePregnane X ReceptorReceptors, Cytoplasmic and NuclearReceptors, SteroidSulfonic Acidsliverperfluorohexane sulfonateperoxisome proliferator-activated receptor-αspecies difference

Identifiers

PMID40036302
PMCPMC12225666

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.